


Healthcare News Roundup: Biopharmaceutical
HSMN NewsFeed - 8 Jul 2019
Skyhawk Therapeutics Announces Expansion of Collaboration Agreement with Biogen
Skyhawk Therapeutics Announces Expansion of Collaboration Agreement with Biogen
HSMN NewsFeed - 8 Jul 2019
Skyhawk Therapeutics Announces Addition of World Leading SAB Head & New VP of Oncology Biology
Skyhawk Therapeutics Announces Addition of World Leading SAB Head & New VP of Oncology Biology
HSMN NewsFeed - 8 Jul 2019
Soligenix Announces Appointment of Diane L. Parks to its Board of Directors
Soligenix Announces Appointment of Diane L. Parks to its Board of Directors
HSMN NewsFeed - 3 Jul 2019
Caris Life Sciences Appoints Steven D. Averbuch, M.D., to Its Scientific Advisory Board
Caris Life Sciences Appoints Steven D. Averbuch, M.D., to Its Scientific Advisory Board
HSMN NewsFeed - 1 Jul 2019
Squarex Appoints Biopharmaceutical Industry Veteran Jack V. Talley as Chief Executive Officer
Squarex Appoints Biopharmaceutical Industry Veteran Jack V. Talley as Chief Executive Officer
HSMN NewsFeed - 28 Jun 2019
Lannett Enters Into Distribution Agreement For Dantrolene Capsules, Commences Product Launch
Lannett Enters Into Distribution Agreement For Dantrolene Capsules, Commences Product Launch
HSMN NewsFeed - 28 Jun 2019
Amgen and UCB Provide Regulatory Update on Status of EVENITY(TM) (romosozumab) in the EU
Amgen and UCB Provide Regulatory Update on Status of EVENITY(TM) (romosozumab) in the EU
HSMN NewsFeed - 27 Jun 2019
DURECT Announces Submission to FDA of a Full Response to the POSIMIR(R) Complete Response Letter
DURECT Announces Submission to FDA of a Full Response to the POSIMIR(R) Complete Response Letter
HSMN NewsFeed - 26 Jun 2019
U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure
U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure
HSMN NewsFeed - 25 Jun 2019
SmartPharm Therapeutics Appoints José Trevejo, MD, PhD, as Chief Executive Officer
SmartPharm Therapeutics Appoints José Trevejo, MD, PhD, as Chief Executive Officer
HSMN NewsFeed - 24 Jun 2019
BioEclipse Therapeutics(TM) Announces Appointment of New Directors and Series A-1 Financing
BioEclipse Therapeutics(TM) Announces Appointment of New Directors and Series A-1 Financing
HSMN NewsFeed - 21 Jun 2019
FDA Approves BOTOX(R) (onabotulinumtoxinA) for Pediatric Patients with Upper Limb Spasticity
FDA Approves BOTOX(R) (onabotulinumtoxinA) for Pediatric Patients with Upper Limb Spasticity
HSMN NewsFeed - 20 Jun 2019
OxThera Initiates Extension Part of a Phase 3 Study of Oxabact in Primary Hyperoxaluria
OxThera Initiates Extension Part of a Phase 3 Study of Oxabact in Primary Hyperoxaluria
HSMN NewsFeed - 19 Jun 2019
HemoShear Therapeutics Names Biopharma Veteran Kathleen M. Metters, PhD, to Board of Directors
HemoShear Therapeutics Names Biopharma Veteran Kathleen M. Metters, PhD, to Board of Directors
HSMN NewsFeed - 19 Jun 2019
CARsgen Therapeutics Receives IND Clearance for BCMA-CAR-T Cells from the U.S. FDA
CARsgen Therapeutics Receives IND Clearance for BCMA-CAR-T Cells from the U.S. FDA
HSMN NewsFeed - 17 Jun 2019
CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy
CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy
HSMN NewsFeed - 14 Jun 2019
SCYNEXIS Appoints Dr. Nkechi Azie as Vice President of Clinical Development
SCYNEXIS Appoints Dr. Nkechi Azie as Vice President of Clinical Development
HSMN NewsFeed - 12 Jun 2019
Sobi Strengthens Focus and Increases Investments in Late-Stage Development in Haematology and Immunology
Sobi Strengthens Focus and Increases Investments in Late-Stage Development in Haematology and Immunology
HSMN NewsFeed - 12 Jun 2019
Zyla Life Sciences Appoints Dr. H. Jeffrey Wilkins as Chief Medical Officer
Zyla Life Sciences Appoints Dr. H. Jeffrey Wilkins as Chief Medical Officer
HSMN NewsFeed - 12 Jun 2019
CutisPharma Announces Acquisition Of Silvergate Pharmaceuticals, Name Change To Azurity Pharmaceuticals
CutisPharma Announces Acquisition Of Silvergate Pharmaceuticals, Name Change To Azurity Pharmaceuticals
HSMN NewsFeed - 11 Jun 2019
GT Apeiron Therapeutics launched by GT Healthcare Capital Partners signs with Exscientia
GT Apeiron Therapeutics launched by GT Healthcare Capital Partners signs with Exscientia
HSMN NewsFeed - 10 Jun 2019
Aridis Pharmaceuticals Appoints Dr. Susan Windham-Bannister to Board of Directors
Aridis Pharmaceuticals Appoints Dr. Susan Windham-Bannister to Board of Directors
HSMN NewsFeed - 4 Jun 2019
Patrick Coyle Appointed Vice President and Chief Financial Officer of Eisai Inc.
Patrick Coyle Appointed Vice President and Chief Financial Officer of Eisai Inc.
HSMN NewsFeed - 3 Jun 2019
Jazz Pharmaceuticals Appoints Dr. Robert Iannone as Executive Vice President, Research and Development
Jazz Pharmaceuticals Appoints Dr. Robert Iannone as Executive Vice President, Research and Development
HSMN NewsFeed - 31 May 2019
Iovance Biotherapeutics Expands Partnership with WuXi Advanced Therapies Business
Iovance Biotherapeutics Expands Partnership with WuXi Advanced Therapies Business
HSMN NewsFeed - 30 May 2019
Emergo Therapeutics Board of Directors Welcomes Jack Bailey, President, GSK Pharmaceuticals USA
Emergo Therapeutics Board of Directors Welcomes Jack Bailey, President, GSK Pharmaceuticals USA
HSMN NewsFeed - 28 May 2019
Medeor Therapeutics Appoints Dr. Karen Smith as President and Chief Executive Officer
Medeor Therapeutics Appoints Dr. Karen Smith as President and Chief Executive Officer
HSMN NewsFeed - 28 May 2019
Lilly Announces Licensing Agreement for Non-Opioid Pain Asset from Centrexion Therapeutics
Lilly Announces Licensing Agreement for Non-Opioid Pain Asset from Centrexion Therapeutics
HSMN NewsFeed - 21 May 2019
Perrigo Announces FDA Final Approval For AB Rated Generic Version Of Voltaren(R) Gel 1%
Perrigo Announces FDA Final Approval For AB Rated Generic Version Of Voltaren(R) Gel 1%
HSMN NewsFeed - 20 May 2019
Reneo Pharmaceuticals Raises $50 Million to Develop Therapeutics to Treat Genetic Mitochondrial Diseases
Reneo Pharmaceuticals Raises $50 Million to Develop Therapeutics to Treat Genetic Mitochondrial Diseases
HSMN NewsFeed - 14 May 2019
Boehringer Ingelheim announces resolution of Cyltezo(R) patent litigation
Boehringer Ingelheim announces resolution of Cyltezo(R) patent litigation
HSMN NewsFeed - 14 May 2019
AbbVie Resolves HUMIRA(R) (adalimumab) U.S. Patent Litigation with Boehringer Ingelheim
AbbVie Resolves HUMIRA(R) (adalimumab) U.S. Patent Litigation with Boehringer Ingelheim
